Clinical data standards vs legacy data
Data standards are a feature of many regulated industries, and the pharmaceutical industry is no exception. But we didn’t always have standards to help us collect, analyze and submit data. Even today, some organizations are not utilizing industry or company standards to ensure their study data is collected the same way every time - despite the many benefits of standardization.
Why are some organizations slow to adopt change?
Arguably, we’re a risk-adverse industry - one that’s constantly adapting to new regulations and often subject to long procurement processes. Change and innovation represent potential risk. Something that many companies aren’t willing to take on. This can lead to a situation where it never feels like the right time to put standards in place.
Many organizations find themselves having to decide between what is best strategically and what is best financially; those without a standards management team must spend large amounts of time and money putting one in place. Sometimes, standardization doesn’t seem like the best approach for a particular study. For example, one that requires content that is not currently part of the standards. In this case, the study may be delayed by the standardization process.
Given the time pressure for getting studies up and running, some organizations or even some study teams are tempted to bypass the standardization process and instead do it their own way.
There’s no doubt that data standards come with their own set of headaches. Particularly for organizations entrenched in traditional processes. But it’s those very standards that have led to the accelerated discovery of new drugs and the delivery of life enhancing or lifesaving treatments to market.
So, what happens when non-standardized data meets clinical data standards?
Before the introduction of CDISC standards, there was no guidance to tell organizations how to collect and format data. It was a ‘free-for-all’, with every company free to create their own study questions and format collected data however they liked.
As a result, organizations were doing the same thing but in different ways. This meant there was no easy way for the US Food and Drug Administration (FDA) to quickly analyze the collected data.
Clinical data standards were developed to ensure that clinical trials were run in a standardized way, from study design and data collection through to analysis.
If you want to find out more about clinical data standards, why not read our blog on CDISC standards used in the clinical research process?
Collecting data in CDISC format
Without industry-wide clinical data standards to guide them, many organizations also didn’t have their own internal organizational data standards. That meant that even within a single organization, data might be collected in a completely different way for each trial. Using the example above, if different teams were designing different studies, one team might use ‘Yes’ or ‘No’ and another team might use ‘Y’ or ‘N’.
CDISC NCI terminology standards were introduced to tackle this problem by standardizing the various allowable responses to questions. The standards specify exactly what the values within the columns should say for every submission. For example, they could specify that studies should use only ‘Y’, ‘N’, or ‘U’ for unknown.
Legacy data mapping
Why might organizations not be using clinical data standards?
- They might be using old or ‘legacy’ data that was collected before the standards existed. This could be data that’s been collected from a previous trial, or data that is no longer ‘active’ but still has a purpose in modern research.
- They might be using data that’s been collected since the inception of data standards, but wasn’t collected in line with those standards are therefore needs to be mapped appropriately. This also applies to data that’s still being collected. For example, if you’ve started a trial using a particular format or specification, you’re unlikely to go back and change it part-way through just because new standards have been introduced.
- A study might be pulling in data from some other external system. For example, via a lab system or a contract research organization (CRO) that doesn’t use CDISC formats. Increasingly, as more and more studies are outsourced to CROs, pharmaceutical companies are facing the challenge of producing very detailed specifications that address how data should be captured and submitted.
- While it isn’t so common nowadays because CDISC standards are so well established, there are still organizations that simply want to continue doing things the way that they’ve always done them. They might copy and paste from a previous spreadsheet at the start of a new study, because they’re used to a familiar format and version. There’s a big problem with this however: over time, they’re falling further and further behind current CDISC standards. They’ll be at a higher risk of errors, inconsistencies and misalignment with SDTM for every study. Ultimately, they’ll face the challenge of unpicking the format and mappings, and having to resolve terminology inconsistencies when it comes to standardizing down the line.
If an organization does find themselves in a situation where important data that they’ve already collected is non-standard, they might face some problems when trying to get that data submission-ready.Problems with mapping terminology
If you’re not collecting data using consistent terminologies that are compatible with CDISC and NCI standards, then you might have trouble mapping the data to those standards.
In another example, an organization may have collected data for a question that has 5 possible answer options. But in the standard terminology, only 4 responses are acceptable. The organization will need to consider how this data should be mapped. Is there a clear lineage between the non-standardized and standardized responses? Or are they incompatible? This situation might require the organization to get more information to work out what standardized term it should map to.Problems with data structure
Quite simply, the structure of the collected non-standardized data might not match with the SDTM structure. This problem is usually fixable, but it will require work to manipulate the structure of the data to fit the standardized rules. For example, you may have to do horizontal-to-vertical transformations; transposing collected data from wide form to lean form, as required by SDTM. Or you might have to combine data from lots of different sources in order to get to the submission structure. Read more about typical mapping scenarios in our blog the SDTM mapping process simplified.
Within an organization that doesn’t adhere to internal data standards, comparison or merging of data can be difficult. There’s a risk that the data collection process is inconsistent. Therefore, mistakes can be made, and you may end up collecting data that is incomplete or unusable. In the worst case, you might discover that you haven’t collected all the data you need, and that you now can’t get that information. To rerun the trial would mean more resources, time and money. This is why it’s always better to base study build on pre-agreed, pre-standardized metadata.
No comments were found for Clinical data standards vs legacy data. Be the first to comment!